Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.96 USD | +1.05% | -7.69% | -23.20% |
Mar. 21 | Earnings Flash (KRON) KRONOS BIO Reports Q4 Revenue $2.3M | MT |
Mar. 21 | Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 5.48M | Sales 2025 * | 3.27M | Capitalization | 57.69M |
---|---|---|---|---|---|
Net income 2024 * | -85M | Net income 2025 * | -94M | EV / Sales 2024 * | 4.96 x |
Net cash position 2024 * | 30.52M | Net Debt 2025 * | 25.18M | EV / Sales 2025 * | 25.3 x |
P/E ratio 2024 * |
-0.62
x | P/E ratio 2025 * |
-0.56
x | Employees | 63 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.5% |
Latest transcript on Kronos Bio, Inc.
1 day | +1.05% | ||
1 week | -7.69% | ||
Current month | -26.15% | ||
1 month | -24.41% | ||
3 months | -18.64% | ||
6 months | +10.34% | ||
Current year | -23.20% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 68 | 18-03-31 | |
Joshua Kazam
FOU | Founder | 47 | 17-06-01 |
David Tanen
FOU | Founder | 52 | 17-06-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Tanen
FOU | Founder | 52 | 17-06-01 |
Joshua Kazam
FOU | Founder | 47 | 17-06-01 |
Arie Belldegrun
FOU | Founder | 74 | 17-06-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 0.96 | +1.05% | 883,997 |
24-04-23 | 0.95 | -1.04% | 4,308,192 |
24-04-22 | 0.96 | -4.95% | 173,041 |
24-04-19 | 1.01 | -1.94% | 119,689 |
24-04-18 | 1.03 | -0.96% | 209,645 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.20% | 57.09M | |
+4.09% | 43.43B | |
+47.81% | 41.69B | |
+9.45% | 41.31B | |
-10.92% | 27.14B | |
+9.32% | 25.28B | |
-24.87% | 18.47B | |
+29.70% | 12.59B | |
+1.28% | 12.33B | |
+7.78% | 11.03B |
- Stock Market
- Equities
- KRON Stock